Immunogen Stock Current Valuation
| IMGNDelisted Stock | USD 18.20 0.81 4.26% |
Valuation analysis of ImmunoGen helps investors to measure ImmunoGen's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that ImmunoGen's price fluctuation is very steady at this time. Calculation of the real value of ImmunoGen is based on 3 months time horizon. Increasing ImmunoGen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ImmunoGen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ImmunoGen Stock. However, ImmunoGen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 18.2 | Real 12.91 | Hype 18.2 | Naive 20.33 |
The intrinsic value of ImmunoGen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ImmunoGen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ImmunoGen helps investors to forecast how ImmunoGen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ImmunoGen more accurately as focusing exclusively on ImmunoGen's fundamentals will not take into account other important factors: ImmunoGen Company Current Valuation Analysis
ImmunoGen's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ImmunoGen Current Valuation | 8.2 B |
Most of ImmunoGen's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmunoGen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, ImmunoGen has a Current Valuation of 8.2 B. This is 42.89% lower than that of the Biotechnology sector and 76.58% higher than that of the Health Care industry. The current valuation for all United States stocks is 50.66% higher than that of the company.
ImmunoGen Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmunoGen's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ImmunoGen could also be used in its relative valuation, which is a method of valuing ImmunoGen by comparing valuation metrics of similar companies.ImmunoGen is currently under evaluation in current valuation category among its peers.
ImmunoGen Fundamentals
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0849 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 8.2 B | |||
| Shares Outstanding | 279.35 M | |||
| Shares Owned By Insiders | 0.32 % | |||
| Shares Owned By Institutions | 91.29 % | |||
| Number Of Shares Shorted | 20.61 M | |||
| Price To Earning | (4.49) X | |||
| Price To Book | 15.53 X | |||
| Price To Sales | 30.33 X | |||
| Revenue | 287.61 M | |||
| Gross Profit | (104.76 M) | |||
| EBITDA | (78.46 M) | |||
| Net Income | (73.52 M) | |||
| Cash And Equivalents | 373.87 M | |||
| Cash Per Share | 1.69 X | |||
| Total Debt | 15.24 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 4.52 X | |||
| Book Value Per Share | 2.06 X | |||
| Cash Flow From Operations | (197.89 M) | |||
| Short Ratio | 3.78 X | |||
| Earnings Per Share | (0.28) X | |||
| Target Price | 31.06 | |||
| Number Of Employees | 277 | |||
| Beta | 1.17 | |||
| Market Capitalization | 8.72 B | |||
| Total Asset | 348.94 M | |||
| Retained Earnings | (1.69 B) | |||
| Working Capital | 182.26 M | |||
| Current Asset | 253.11 M | |||
| Current Liabilities | 60.44 M | |||
| Net Asset | 348.94 M |
About ImmunoGen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmunoGen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoGen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoGen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ImmunoGen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmunoGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmunoGen will appreciate offsetting losses from the drop in the long position's value.Moving together with ImmunoGen Stock
Moving against ImmunoGen Stock
| 0.79 | PPERF | Bank Mandiri Persero | PairCorr |
| 0.79 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.73 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
| 0.72 | BKRKF | PT Bank Rakyat | PairCorr |
| 0.65 | BKRKY | Bank Rakyat | PairCorr |
The ability to find closely correlated positions to ImmunoGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ImmunoGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ImmunoGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ImmunoGen to buy it.
The correlation of ImmunoGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ImmunoGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ImmunoGen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ImmunoGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |